Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The company is keeping its payout steady, despite declines in headline fundamentals in its Q2.

Dividend Aristocrat Johnson & Johnson Declares Fresh Dividend; Yield Is 2.7%

NEW BRUNSWICK, N.J., July 20, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2020 of $1.01 per share on the company's common stock.

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2020

Johnson & Johnson: A Core Dividend Growth Stock With Risks

JNJ is a Dow Jones Industrial Average component that makes consumer packaged goods, medical devices, and pharmaceuticals.

Johnson & Johnson: This Dividend Aristocrat Is Ready To Break Out

Colgate-Palmolive

General Dynamics

The coronavirus pandemic didn't stop these giants from giving dividend investors what they want.

These 3 Dividend Aristocrats Have Already Boosted Their Payouts in 2020

BioNTech SE

Moderna

Sanofi

The European Union is negotiating advance purchase deals of potential COVID-19 vaccines with drugmakers Moderna , Sanofi and Johnson & Johnson as well as biotech firms BioNtech and CureVac, two EU sources told Reuters.

Exclusive: EU in talks with Moderna, BioNtech, CureVac to secure possible COVID vaccines

Investors typically look at J&J's (JNJ) results for signals about how the rest of the big drugmakers will fare.

J&J Sets in Motion Pharma Q2 Earnings: 3 Stocks to Buy

Mastercard

Microsoft

When investing for the long-term, investors should prize stocks with strong management, wide moats and plenty of growth levers.

3 Best Long-Term Stocks to Set and Forget

Johnson & Johnson (NYSE: JNJ) said Thursday it would begin late-stage human trials for its COVID-19 vaccine ahead of schedule in September, with the phase one trials involving 1,000 people set to begin next week.

Johnson & Johnson Says Late-Stage Coronavirus Vaccine Trials Moved Ahead To September

Johnson & Johnson (JNJ) CEO Alex Gorsky on Q2 2020 Results - Earnings Call Transcript

The pandemic took some wind out of the healthcare conglomerate's sails, but its results weren't as bad as expected.

Johnson & Johnson's Revenue and Earnings Slipped in the Second Quarter

Johnson & Johnson (JNJ) earnings for Q2 2020 have the pharmaceutical and consumer goods company's stock on the move Thursday.
The post JNJ Stock: 4 Things to Know About Johnson & Johnson Q2 Earnings appeared first on InvestorPlace.

JNJ Stock: 4 Things to Know About Johnson & Johnson Q2 Earnings

Apple

Cisco Systems

J&J raised its outlook despite a big sales hit due to the pandemic, and the two tech giants underperformed the market.

Dow Jones Slumps as Johnson & Johnson Boosts Outlook, Apple and Cisco Stocks Head Lower

Johnson & Johnson’s 2nd-Quarter Earnings and Revenue Beat Expectations

Johnson & Johnson Inc is in talks with the government of Japan and the Bill and Melinda Gates Foundation about locking up allocations of its potential COVID-19 vaccine in advance of it producing any of the medicines, Johnson & Johnson's chief financial officer Joseph Wolk told Reuters in an interview.

Exclusive: J&J says in talks with Japan, Gates Foundation to lock in deals on COVID-19 vaccine

Johnson & Johnson (NYSE: JNJ) released its most recent quarterly results before the markets opened on Thursday.

Johnson & Johnson’s Impressive Quarter, Still Held Back by One Segment

Johnson & Johnson said on Thursday it is aiming to begin in September a late-stage study of its experimental vaccine for the novel coronavirus, as researchers work at break-neck speed to develop a shot to combat the fast-spreading pathogen.

J&J says large study of coronavirus vaccine could begin in September

J&J (JNJ) beats second-quarter 2020 estimates for both earnings and sales. It increases its adjusted earnings and sales outlook for 2020.

J&J (JNJ) Beats on Q2 Earnings & Sales, Ups 2020 Guidance

Johnson & Johnson (NYSE: JNJ) published its quarterly results on Thursday that highlighted a 35% year over year decline in its profit in the fiscal second quarter. The company attributed the decline to the Coronavirus pandemic that minimised elective surgeries in recent months and weighed on J&J’s medical device business.

Johnson & Johnson’s profit tanks 35% in Q2 as COVID-19 delays elective surgeries

Johnson & Johnson said it expects to begin a late-stage human trial for a potential coronavirus vaccine in late September, ahead of schedule.

Johnson & Johnson expects to begin late-stage coronavirus vaccine trial ahead of schedule in late September

Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 11.33% and 4.37%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Johnson & Johnson (JNJ) Q2 Earnings and Revenues Beat Estimates

Shares of Johnson & Johnson JNJ, +0.23% were down 0.3% in premarket trading on Thursday after CFO Joseph Wolk told CNBC that the company expects the Phase 1 trial for its COVID-19 vaccine candidate to begin next week.

J&J to start Phase 1 trial for coronavirus vaccine candidate next week

Shares of Johnson & Johnson (NYSE:JNJ) moved higher by 0.1% in pre-market trading after the company reported Q2 results.

Recap: Johnson & Johnson Q2 Earnings

Johnson & Johnson earnings and sales beat Q2 views, with the Dow Jones giant raising 2020 guidance. JNJ stock edged higher before the open.

Johnson & Johnson Earnings Top; Dow Jones Giant Raises Full-Year Guidance

Johnson & Johnson’s second-quarter profit slid 35% from the same time last year as the coronavirus pandemic forced hospitals to postpone elective surgeries, hitting the company’s medical device business hard.

News for Johnson & Johnson Stock (JNJ)